A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee
By setting clear, measurable, and individualised treatment targets supported by shared decision-making, regular monitoring and treatment optimisation as needed, this consensus-derived T2T algorithm aims to promote more consistent care within the HAE community and ultimately improve patient outcomes.
Authors
- Efrem Eren
- Sorena Kiani‐Alikhan (ORCID: https://orcid.org/0000-0002-1299-4415)
- Johanna Mandelin (ORCID: https://orcid.org/0000-0002-3816-1809)
- Teresa Caballero (ORCID: https://orcid.org/0000-0003-3005-9858)
- Mauro Cancian
- David Launay
- T. Buttgereit
- Danny Cohn
- Andrea Zanichelli
- Isabelle Boccon-Gibod
- Henriette Farkas
Institutions
- Semmelweis University (HU)
- University of Padua (IT)
- Royal Free London NHS Foundation Trust (GB)
- University of Milan (IT)
- Helsinki University Hospital (FI)
- University Hospital Southampton NHS Foundation Trust (GB)
- Centre Hospitalier Universitaire de Lille (FR)
- IRCCS Policlinico San Donato (IT)
- Hospital La Paz Institute for Health Research (ES)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Laboratoire National de Référence (MA)
- Amsterdam University Medical Centers (NL)
- Charité - Universitätsmedizin Berlin (DE)
- University of Amsterdam (NL)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.3389/fimmu.2026.1773279
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Sanofi
- CSL Behring
- Celltrion Healthcare
- Ionis Pharmaceuticals
- BioCryst
- Celltrion
- Galderma
- Ono Pharmaceutical
- Medac
- Dr. Falk Pharma